Ken Griffin Citius Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$0.58 - $1.03 $14,325 - $25,441	24,700 New	24,700 $14,000
Q4 2023 Feb 14, 2024	BUY	$0.65 - $0.86 $2,795 - $3,698	4,300 Added 81.13%	9,600 $7,000
Q3 2023 Nov 14, 2023	BUY	$0.65 - $1.25 $3,120 - $6,000	4,800 Added 960.0%	5,300 $3,000
Q2 2023 Aug 14, 2023	SELL	$1.08 - $1.65 $19,764 - $30,195	-18,300 Reduced 97.34%	500 $0
Q1 2023 May 15, 2023	SELL	$0.78 - $1.42 $149,058 - $271,362	-191,100 Reduced 91.04%	18,800 $21,000
Q4 2022 Feb 14, 2023	SELL	$0.79 - $1.28 $1,343 - $2,176	-1,700 Reduced 0.8%	209,900 $165,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $1.33 $5,908 - $56,126	42,200 Added 24.91%	211,600 $256,000

30.6M

24.7K

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $65.8M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.